Description
Thymosin Alpha-1 (Tα1)
- A 28-amino-acid synthetic peptide fragment, originally isolated from thymosin fraction 5 of calf thymus tissue; identical in sequence to a portion of the endogenous human prothymosin alpha protein.
- Primarily studied as an immunomodulator. It’s proposed to enhance T-cell maturation and function, promote dendritic cell activity, and modulate cytokine production, helping the immune system respond more effectively to infections, vaccines, and certain cancers, while also having some regulatory (anti-inflammatory) effects to prevent excessive immune activation.
- Mechanistically, it acts on toll-like receptors (TLR2/TLR9) and influences NF-κB and other signaling pathways involved in innate and adaptive immunity.
- Route: typically administered subcutaneously in the contexts where it’s studied clinically.
Regulatory/evidence status: Thymosin alpha-1 is further along than many research peptides — it’s marketed under the brand name Zadaxin and is approved in several countries (including parts of Asia, South America, and elsewhere) for indications like chronic hepatitis B/C (as an adjunct to antiviral therapy) and as an immune adjuvant in some cancer and vaccine-response contexts. However, it is not FDA-approved in the United States; a Phase 3 trial (RESPITE) evaluating it as an adjunct in severe sepsis did not meet its primary endpoint. In the US it’s generally available only through compounding pharmacies or as a research-use compound, so the regulatory picture is a patchwork rather than uniform global approval.
